LOGIN  |  REGISTER
C4 Therapeutics
Chimerix

Media Advisory: UnitedHealth Group Responds to Misinformation

December 13, 2024 | Last Trade: US$525.00 10.75 2.09

- / Dec 13, 2024 / Business Wire / UnitedHealth Group today issued the following update:

Claims approval rates

  • UnitedHealthcare approves and pays about 90% of medical claims upon submission. Importantly, of those that require further review, around one-half of one percent are due to medical or clinical reasons. Highly inaccurate and grossly misleading information has been circulated about our company’s treatment of insurance claims.

Whether the killer and his parents were UnitedHealthcare members

  • Regarding the murder of Brian Thompson, we are re-affirming that the killer and his parents were not UnitedHealthcare members.

We grieve the passing of our dear friend and colleague and continue to work closely with law enforcement and their investigation of this horrific crime.

About UnitedHealth Group

UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page